Zymeworks (NASDAQ:ZYME) Issues Quarterly Earnings Results

Zymeworks (NASDAQ:ZYME) issued its earnings results on Thursday. The company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.49), FiscalAI reports. Zymeworks had a negative return on equity of 33.52% and a negative net margin of 126.92%.The firm had revenue of $2.41 million during the quarter, compared to analysts’ expectations of $24.38 million. During the same quarter in the prior year, the company posted ($0.30) earnings per share. Zymeworks’s quarterly revenue was down 91.1% compared to the same quarter last year.

Here are the key takeaways from Zymeworks’ conference call:

• Zanidatamab regulatory catalysts: U.S. PDUFA is set for August 25, 2026 for first‑line HER2+ GEA and an sBLA was completed in China, creating near‑term commercialization visibility and expected partner milestone payments (approximately $250M U.S., $50M China).
• Pan‑RAS ADC platform progress: AACR disclosed three new pan‑RAS ADC candidates with a proprietary payload showing tumor‑selective accumulation, durable pathway inhibition, and encouraging non‑human primate tolerability, supporting further development across RAS‑driven cancers.
• ZW191 clinical signal: Phase I data showed strong activity in heavily pretreated ovarian (ORR 56% overall; 61% at 6.4–9.6 mg/kg) and endometrial cancer (ORR 40% overall; 57% at 6.4–9.6 mg/kg) with manageable cytopenias/GI events and ongoing dose optimization.
• Financial results show volatility: revenue fell to $2.4M (Q1 2026) from $27.1M a year earlier and net loss widened to $44.2M, driven by the absence of non‑recurring 2025 milestones and declines in development support.
• Balance sheet and capital deployment: Cash and marketable securities were $403.8M at March 31, 2026, ~$95.8M of a $125M buyback executed (≈3.93M shares), and management expects runway beyond 2028 assuming anticipated milestone payments (~$440M), supporting buybacks, partnerships, or M&A optionality.

Zymeworks Stock Performance

Shares of NASDAQ ZYME opened at $23.89 on Friday. The business has a 50-day simple moving average of $25.62 and a two-hundred day simple moving average of $24.06. The company has a market cap of $1.76 billion, a PE ratio of -17.44 and a beta of 1.20. Zymeworks has a fifty-two week low of $10.93 and a fifty-two week high of $29.75.

Wall Street Analyst Weigh In

ZYME has been the subject of several research reports. Wells Fargo & Company upped their price target on shares of Zymeworks from $33.00 to $34.00 and gave the stock an “overweight” rating in a research report on Friday. Stifel Nicolaus upped their price target on shares of Zymeworks from $40.00 to $47.00 and gave the stock a “buy” rating in a research report on Tuesday, March 3rd. Leerink Partners upped their price objective on Zymeworks from $52.00 to $58.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 3rd. Truist Financial upgraded Zymeworks to a “strong-buy” rating in a research note on Monday, April 27th. Finally, HC Wainwright upped their price objective on Zymeworks from $32.00 to $46.00 and gave the stock a “buy” rating in a research note on Friday, March 6th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Zymeworks presently has an average rating of “Moderate Buy” and an average price target of $38.00.

Institutional Trading of Zymeworks

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Invesco Ltd. raised its position in Zymeworks by 175.0% during the fourth quarter. Invesco Ltd. now owns 257,580 shares of the company’s stock valued at $6,782,000 after acquiring an additional 163,923 shares in the last quarter. XTX Topco Ltd purchased a new position in Zymeworks during the fourth quarter valued at approximately $2,461,000. VARCOV Co. purchased a new position in Zymeworks during the fourth quarter valued at approximately $259,000. Virtus Investment Advisers LLC raised its position in Zymeworks by 20.2% during the fourth quarter. Virtus Investment Advisers LLC now owns 10,441 shares of the company’s stock valued at $275,000 after acquiring an additional 1,755 shares in the last quarter. Finally, SummitTX Capital L.P. purchased a new position in Zymeworks during the fourth quarter valued at approximately $5,905,000. Institutional investors and hedge funds own 92.89% of the company’s stock.

Zymeworks Company Profile

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. The company specializes in engineered antibody and protein therapeutics designed to address a range of unmet medical needs in oncology and other serious diseases. Through its proprietary platforms, Zymeworks aims to create novel bispecific and multispecific molecules that can simultaneously engage multiple targets and recruit immune effector functions to enhance potency and specificity.

At the core of Zymeworks’ innovation is its Azymetric™ bispecific antibody platform, which enables the design of asymmetrical bispecific antibodies with controlled assembly and high stability.